www.marijuanamoment.net
Open in
urlscan Pro
2606:4700:3035::ac43:d621
Public Scan
URL:
https://www.marijuanamoment.net/new-fda-report-highlights-how-marijuana-rescheduling-review-analyzed-cannabis-users-social-media...
Submission Tags: conservative right wing conservatives gop republican republicans trump election maga human rights Search All
Submission: On February 19 via manual from US — Scanned from CA
Submission Tags: conservative right wing conservatives gop republican republicans trump election maga human rights Search All
Submission: On February 19 via manual from US — Scanned from CA
Form analysis
3 forms found in the DOMGET https://www.marijuanamoment.net/
<form method="get" id="searchform" action="https://www.marijuanamoment.net/">
<input type="text" name="s" id="s" value="Search" onfocus="if (this.value == "Search") { this.value = ""; }" onblur="if (this.value == "") { this.value = "Search"; }">
<input type="hidden" id="searchsubmit" value="Search">
</form>
POST
<form id="mc4wp-form-2" class="mc4wp-form mc4wp-form-869" method="post" data-id="869" data-name="Marijuana News In Your Inbox">
<div class="mc4wp-form-fields">Get our daily newsletter. <p>
<label>Email address: </label>
<input type="email" name="EMAIL" placeholder="Your email address" required="">
</p>
<p>
<input type="submit" value="Sign up">
</p>
</div><label style="display: none !important;">Leave this field empty if you're human: <input type="text" name="_mc4wp_honeypot" value="" tabindex="-1" autocomplete="off"></label><input type="hidden" name="_mc4wp_timestamp"
value="1708362715"><input type="hidden" name="_mc4wp_form_id" value="869"><input type="hidden" name="_mc4wp_form_element_id" value="mc4wp-form-2">
<div class="mc4wp-response"></div>
</form>
POST
<form id="mc4wp-form-3" class="mc4wp-form mc4wp-form-869" method="post" data-id="869" data-name="Marijuana News In Your Inbox">
<div class="mc4wp-form-fields">Get our daily newsletter. <p>
<label>Email address: </label>
<input type="email" name="EMAIL" placeholder="Your email address" required="">
</p>
<p>
<input type="submit" value="Sign up">
</p>
</div><label style="display: none !important;">Leave this field empty if you're human: <input type="text" name="_mc4wp_honeypot" value="" tabindex="-1" autocomplete="off"></label><input type="hidden" name="_mc4wp_timestamp"
value="1708362715"><input type="hidden" name="_mc4wp_form_id" value="869"><input type="hidden" name="_mc4wp_form_element_id" value="mc4wp-form-3">
<div class="mc4wp-response"></div>
</form>
Text Content
* Politics * Science & Health * Culture * Business * Video * Newsletter * Subscribe * Remove Ads * Bill Tracking * About * Login Instructions * All 2024 Cannabis Bills * Bill Hearing Calendar * About Marijuana Moment * Support Marijuana Moment * Subscribe To Newsletter Connect with us * * * MARIJUANA MOMENT NEW FDA REPORT HIGHLIGHTS HOW MARIJUANA RESCHEDULING REVIEW ANALYZED CANNABIS USERS’ SOCIAL MEDIA POSTS * Politics * Hawaii Panel Advances Therapeutic Psilocybin Bill That Would Protect Patients From Penalties * How Virginia’s Competing Marijuana Sales Bills Differ On Licensing, Equity, Taxes And More * New FDA Report Highlights How Marijuana Rescheduling Review Analyzed Cannabis Users’ Social Media Posts * Alabama Medical Marijuana Access Could Take Months, Even After Licensing Lawsuits End * Advice For The Marijuana Movement And Industry From A Retiring Activist (Op-Ed) * Science & Health * Marijuana Tax Revenue Should Fund Education And Housing, Not Police And Prisons, Voters Say In New Poll * Federally Funded Researchers Discover Two New Methods Of Distinguishing Hemp And Marijuana To Assist Crime Labs * Search Interest In Delta-8 THC Nearly Twice As High In States Without Legal Marijuana, Study Finds * Psilocybin, LSD And Other Psychedelics Improve Sexual Satisfaction For Months After Use, New Study Finds * New Study Shows How Marijuana Compounds Like Cannabinoids, Terpenes And Flavonoids Interact For Medical Benefits * Culture * Rapper Killer Mike Suggests Giving Black People Control Over Marijuana Industry As A Form Of Reparations * Brooklyn Nets And New York Liberty Become First NBA And WNBA Teams To Partner With CBD Company * UFC Warns Fighters To Stop Using Marijuana ‘Immediately’ So They Aren’t Punished Under California Athletics Rules * Treasury Secretary Yellen Says She Over-Prepared For First Time Using Marijuana And Jokes That It ‘Always Helps’ With Candy Crush * NFL Partnering On New Study Using CBD To Treat Pain And Protect From Concussions * Business * Missouri Marijuana Company Argues That Workers Are Not Allowed To Unionize Due To Federal Law * Multiple States Across The Country See Record-Breaking Marijuana Sales To Close Out 2023 * Massachusetts Sets Marijuana Sales Record In December, With Total Purchases In 2023 Reaching $1.8 Billion * Missouri Sold More Than $1.3 Billion Worth Of Legal Marijuana In 2023, State Figures Show * Michigan Marijuana Sales Surpassed $3 Billion In 2023 As Retailers Smashed Monthly Record In December * Video * Hawaii Panel Advances Therapeutic Psilocybin Bill That Would Protect Patients From Penalties * FDA Officials Join Experts To Discuss Psychedelics Research Challenges And Promises * New York Officials Approve Marijuana Home Grow Rules And New Business Licenses Amid ‘Rocky Start’ For Legal Market * Minnesota Republicans Warn Of ‘Blackouts And Brownouts’ From Marijuana Cultivation’s Energy Use * Maryland Senate Committee Approves Bill To Protect Medical Marijuana Patients’ Gun Rights Under State Law * Newsletter * VP Harris reaching out to cannabis pardon recipients (Newsletter: February 19, 2024) * DOJ’s new marijuana & hemp testing methods (Newsletter: February 16, 2024) * German legal cannabis vote scheduled (Newsletter: February 15, 2024) * Cannabis rescheduling won’t violate treaties, memo says (Newsletter: February 14, 2024) * PA has no choice but to legalize cannabis, gov says (Newsletter: February 13, 2024) * Subscribe * Remove Ads * Bill Tracking * About * Login Instructions * All 2024 Cannabis Bills * Bill Hearing Calendar * About Marijuana Moment * Support Marijuana Moment * Subscribe To Newsletter POLITICS NEW FDA REPORT HIGHLIGHTS HOW MARIJUANA RESCHEDULING REVIEW ANALYZED CANNABIS USERS’ SOCIAL MEDIA POSTS Published 4 hours ago on February 19, 2024 By Kyle Jaeger The Food and Drug Administration (FDA) is highlighting its scientific review into marijuana that led the agency to recommend rescheduling—a process that involved a comprehensive analysis of research, as well looking at hundreds of posts on social media platforms to see how consumers described cannabis’s therapeutic impact. In its 2023 fiscal year Drug Safety Priorities report that was published on Thursday, FDA’s Center for Drug Evaluation and Research (CDER) discussed various initiatives that it says illustrate “the depth and versatility of drug safety initiatives across the Center and FDA.” That includes the cannabis analysis it conducted under a 2022 directive from President Joe Biden. CDER said its staff “conducted an expansive review of numerous data sources to inform a scientific and medical assessment called an Eight Factor analysis (8FA),” and the results “informed FDA’s recommendation to the Drug Enforcement Administration (DEA) to down-schedule marijuana to Schedule III” from Schedule I under the Controlled Substances Act. Cannabis café bill gets reintroduced Cannabis café bill gets reintroduced California Assemblymember Matt Haney has reintroduced a bill to create Amsterdam-style cannabis cafes in the state. Governor Newsom vetoed a similar bill last year, which would have allowed cannabis dispensaries to sell food and host live concerts. Assemblymember Haney joined us on 'The Nine' to talk about how it could reshape the cannabis landscape across California. More Videos 0 seconds of 7 minutes, 31 secondsVolume 0% Press shift question mark to access a list of keyboard shortcuts Keyboard ShortcutsEnabledDisabled Play/PauseSPACE Increase Volume↑ Decrease Volume↓ Seek Forward→ Seek Backward← Captions On/Offc Fullscreen/Exit Fullscreenf Mute/Unmutem Decrease Caption Size- Increase Caption Size+ or = Seek %0-9 Next Up Ohio Releases First Set Of Proposed Marijuana Rules: Regulators Seek Feedback 00:46 facebook twitter Email pinterest Linkhttps://cdn.jwplayer.com/previews/qZiu3IRj Copied Live 00:00 01:48 07:31 “As part of CDER’s cross-center evaluation of marijuana, the CDER Office of Surveillance and Epidemiology (OSE) completed a review of epidemiologic and pharmacovigilance data sources to inform the 8FA provided to DEA,” it said. After the conclusion of the FDA review, the U.S. Department of Health and Human Services (HHS) submitted a letter with hundreds of pages of research material to DEA with the Schedule III recommendation. DEA is now carrying out its own review before making a final determination. There were rumors that the decision would be announced two weeks ago, but a Biden administration official told Marijuana Moment said they’d “wave off” that speculation. FDA’s work to reach a scheduling conclusion also involved a team of social scientists who spent six months conducting a “detailed qualitative analysis of online and social media conversations occurring about marijuana,” the report says. “This six-month study involved manually analyzing hundreds of posts on publicly available online/social media platforms to provide context directly from users regarding marijuana, including its effectiveness for several therapeutic purposes such as anorexia, anxiety, nausea, and pain; nonmedical purposes; benefits and negative effects, experiences with access,” it says. Separately, the new FDA report said the agency “completed an assessment of the capabilities and usefulness of a variety of epidemiologic, pharmacovigilance, and drug utilization data sources for monitoring the safety of unapproved cannabis-derived products.” It’s been nearly six months since FDA provided DEA with is marijuana rescheduling recommendation, but the timing of a final decision is uncertain. In the interim, Congressional Cannabis Caucus founder Rep. Earl Blumenauer (D-OR) recently urged the agency to release more information about its ongoing review—including what its “planned deadline” is for finishing and whether it will take into account the fact that many states have already legalized cannabis. The correspondence came in response to a recent assertion from DEA that it has “final authority” on the rescheduling decision—which itself was a reply to a separate letter from Blumenauer and 30 other bipartisan lawmakers. On the other side of the issue, a Republican congressman who has long opposed marijuana reform claimed in a letter to DEA that FDA came to a “misguided conclusion” to recommend rescheduling cannabis, challenging the health agency’s scientific standards and imploring DEA to dismiss them as it prepares to make a final determination. A separate letter sent to DEA Administrator Anne Milgram this month—led by Sens. Elizabeth Warren (D-MA) and John Fetterman (D-PA), along with Senate Majority Leader Chuck Schumer (D-NY) and other champions of marijuana reform—urged DEA to go further than rescheduling by fully removing cannabis from the CSA. Meanwhile, HHS Secretary Xavier Becerra said last month that his agency has “communicated” its “position” on marijuana rescheduling to DEA and has continued to offer additional information to assist with the final determination. Prior to HHS releasing a trove of documents concerning its cannabis recommendation, a coalition of 12 Democratic state attorneys general implored DEA to move forward with federal marijuana rescheduling, calling the policy change a “public safety imperative.” In another letter in December, 29 former U.S. attorneys called on the Biden administration to leave cannabis in Schedule I. Also that month, the governors of six U.S. states—Colorado, Illinois, New York, New Jersey, Maryland and Louisiana—sent a letter to Biden calling on the administration to reschedule marijuana by the end of last year. Meanwhile, six former DEA heads and five former White House drug czars sent a letter to the attorney general and current DEA administrator voicing opposition to the top federal health agency’s recommendation to reschedule marijuana. They also made a questionable claim about the relationship between drug schedules and criminal penalties in a way that could exaggerate the potential impact of the incremental reform. Signatories include DEA and Office of National Drug Control Policy heads under multiple administrations led by presidents of both major parties. A coalition of 14 Republican congressional lawmakers, meanwhile, separately urged DEA to “reject” the top federal health agency’s recommendation to reschedule marijuana and instead keep it in the most restrictive category under the CSA. A recent poll found that about one-third of marijuana consumers say they would go back to the illicit market if cannabis was rescheduled and only made legally available as an FDA-approved prescription drug. Another recent survey found that President Joe Biden stands to make significant political gains if marijuana is rescheduled under his administrative directive. Of course, Biden doesn’t directly control the final outcome. The president has routinely touted his 2022 scheduling directive, as well as a mass pardon he granted for people who’ve committed federal marijuana possession offenses. He followed up on that action in December with a renewed and expanded pardon proclamation. The Justice Department has already begun issuing certifications for people who applied under the second round. Vice President Kamala Harris’s office has been reaching out to people who’ve received a cannabis pardon—seeking assurance that the Justice Department certification process is going smoothly and engaging in broader discussions about cannabis policy reform, according to a pardon recipient who was contacted. > FDA Officials Join Experts To Discuss Psychedelics Research Challenges And > Promises Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge. Related Topics:featured Up Next How Virginia’s Competing Marijuana Sales Bills Differ On Licensing, Equity, Taxes And More Don't Miss Alabama Medical Marijuana Access Could Take Months, Even After Licensing Lawsuits End Kyle Jaeger Kyle Jaeger is Marijuana Moment's Sacramento-based managing editor. His work has also appeared in High Times, VICE and attn. YOU MAY LIKE Hawaii Panel Advances Therapeutic Psilocybin Bill That Would Protect Patients From Penalties How Virginia’s Competing Marijuana Sales Bills Differ On Licensing, Equity, Taxes And More VP Harris reaching out to cannabis pardon recipients (Newsletter: February 19, 2024) Alabama Medical Marijuana Access Could Take Months, Even After Licensing Lawsuits End Advice For The Marijuana Movement And Industry From A Retiring Activist (Op-Ed) FDA Officials Join Experts To Discuss Psychedelics Research Challenges And Promises Advertisement MARIJUANA NEWS IN YOUR INBOX Get our daily newsletter. Email address: Leave this field empty if you're human: SUPPORT MARIJUANA MOMENT * * * * About Marijuana Moment * Subscribe * Sponsorship and Advertising * Privacy Policy All the cannabis news you need, all in one place. Copyright © 2017-2024 Marijuana Moment LLC ® and Tom Angell Information from your device can be used to personalize your ad experience. Do not sell or share my personal information. A Raptive Partner Site MARIJUANA NEWS IN YOUR INBOX Get our daily newsletter. Email address: Leave this field empty if you're human: ✕ Do not sell or share my personal information. You have chosen to opt-out of the sale or sharing of your information from this site and any of its affiliates. To opt back in please click the "Customize my ad experience" link. This site collects information through the use of cookies and other tracking tools. Cookies and these tools do not contain any information that personally identifies a user, but personal information that would be stored about you may be linked to the information stored in and obtained from them. This information would be used and shared for Analytics, Ad Serving, Interest Based Advertising, among other purposes. For more information please visit this site's Privacy Policy. CANCEL CONTINUE